Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew L. Hopkins is active.

Publication


Featured researches published by Andrew L. Hopkins.


Structure | 1995

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.

Jingshan Ren; Robert M. Esnouf; Andrew L. Hopkins; C. Ross; Yvonne Jones; David K. Stammers; David I. Stuart

BACKGROUNDnHIV reverse transcriptase (RT) is a key target of anti-AIDS therapies. Structural studies of HIV-1 RT, unliganded and complexed with different non-nucleoside inhibitors (NNIs), have pointed to a common mode of binding and inactivation through distortion of the polymerase catalytic site by NNIs containing two hinged rings. The mode of binding of the TIBO family of inhibitors is of interest because these compounds do not fit the two-hinged-ring model.nnnRESULTSnThe structure of HIV-1 RT complexed with 9-chloro-TIBO (R82913) has been determined at 2.6 A resolution. As reported for the lower resolution analysis of another TIBO compound, this inhibitor binds at the same site as other NNIs, but our higher resolution study reveals the Cl-TIBO is distorted from the conformation seen in crystals of the inhibitor alone. This allows Cl-TIBO to mimic the binding of NNIs containing two hinged rings. Inhibitor-protein interactions are again predominantly hydrophobic and the protein conformation corresponds to that seen in complexes with other tight-binding NNIs.nnnCONCLUSIONSnAlthough Cl-TIBO is chemically very different from other NNIs, it achieves remarkable spatial equivalence and shape complementarity with other NNIs on binding to RT. Comparison of the different RT-NNI complexes suggests modifications to the TIBO group of inhibitors which might enhance their binding and hence, potentially, their therapeutic efficacy.


Journal of Medicinal Chemistry | 1996

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.

Andrew L. Hopkins; Jingshan Ren; Robert M. Esnouf; Benjamin E. Willcox; E.Y. Jones; C. Ross; Tadashi Miyasaka; R. T. Walker; Hiromichi Tanaka; David K. Stammers; David I. Stuart


Proceedings of the National Academy of Sciences of the United States of America | 1997

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.

Robert M. Esnouf; Junyuan Ren; Andrew L. Hopkins; C. Ross; E.Y. Jones; David K. Stammers; David I. Stuart


Journal of Medicinal Chemistry | 1999

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.

Andrew L. Hopkins; Jingshan Ren; Hiromichi Tanaka; Masanori Baba; Mika Okamato; David I. Stuart; David K. Stammers


Biochemistry | 1998

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.

Jingshan Ren; Robert M. Esnouf; Andrew L. Hopkins; Jonathan Warren; Jan Balzarini; David I. Stuart; David K. Stammers


Journal of Medicinal Chemistry | 2004

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

Andrew L. Hopkins; Jingshan Ren; John Milton; Richard J. Hazen; Joseph H. Chan; David I. Stuart; David K. Stammers


Proceedings of the National Academy of Sciences of the United States of America | 1998

3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes

Jingshan Ren; Robert M. Esnouf; Andrew L. Hopkins; E.Y. Jones; I. Kirby; J. Keeling; C. Ross; Brendan A. Larder; David I. Stuart; David K. Stammers


Journal of Medicinal Chemistry | 2001

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Joseph H. Chan; Jean S. Hong; Robert Neil Hunter; G. Faye Orr; Jill R. Cowan; Douglas B. Sherman; Steven M. Sparks; Barbara E. Reitter; C. Webster Andrews; Richard J. Hazen; Marty St. Clair; Lawrence R. Boone; Rob G. Ferris; Katrina L. Creech; Grace B. Roberts; Steven A. Short; Kurt Weaver; Ronda J. Ott; Jingshan Ren; Andrew L. Hopkins; David I. Stuart; David K. Stammers


Journal of Medicinal Chemistry | 1999

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.

Jingshan Ren; Robert M. Esnouf; Andrew L. Hopkins; David I. Stuart; David K. Stammers


Acta Crystallographica Section A | 1996

Conformational changes in HIV-1 reverse transcriptase relevant to the design of potent inhibitors

Andrew L. Hopkins; Junyuan Ren; Robert M. Esnouf; C. Ross; E.Y. Jones; David K. Stammers; David I. Stuart

Collaboration


Dive into the Andrew L. Hopkins's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

David K. Stammers

Wellcome Trust Centre for Human Genetics

View shared research outputs
Top Co-Authors

Avatar

Jingshan Ren

Wellcome Trust Centre for Human Genetics

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge